SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated ...
Primary endpoint met in first randomized Phase 2 study, FOURLIGHT-1, showing a 40% reduction in the risk of disease progression or death with manageable safety profile More than 90% of patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results